Business
Syndax Announces Participation in BTIG Virtual Biotechnology Conference
WALTHAM, Mass., Aug. 3, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., Aug. 3, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Monday, August 10, 2020 at 12:00 p.m. ET.\nA live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time. \nAbout Syndax Pharmaceuticals, Inc. \nSyndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. \nSyndax Contacts\nInvestor ContactMelissa ForstArgot [email protected] 212.600.1902\nMedia ContactTed [email protected] Tel 212.798.9842\nSNDX-G\n View original content:http://www.prnewswire.com/news-releases/syndax-announces-participation-in-btig-virtual-biotechnology-conference-301104238.html\nSOURCE Syndax Pharmaceuticals, Inc.","length":6101,"tagName":"div"}]